公开(公告)号：US20240033244A1

公开(公告)日：2024-02-01

申请号：US18004623

申请日：2021-07-08

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  HANGZHOU LEADING EDGE PHARMACEUTICAL LTD. ,  SHANGHAI KANGQIAN BIOTECHNOLOGY LIMITED

发明人： Cheng LUO ,  Meng XU ,  Shijie CHEN ,  Yilin LI ,  Yantao CHEN ,  Hualiang JIANG ,  Kaixian CHEN ,  Zhanpeng JIANG

IPC分类号： A61K31/343 ,  A61K35/15 ,  A61K39/395 ,  A61K31/216 ,  A61P35/00

CPC分类号： A61K31/343 ,  A61K35/15 ,  A61K39/3955 ,  A61K31/216 ,  A61P35/00

摘要： A YTH N6-Methyladenosine RNA Binding Protein 1 (YTHDF1) attenuating agent, with a compound, and when bound to YTHDF1, the compound binds to amino acid residues 372-392, 479-494 and 526-535 of SEQ ID NO: 1. A modified antigen presenting cell (mAPC), with the mAPC being treated with a YTHDF1 attenuating agent. A composition, with a YTHDF1 attenuating agent, a mAPC treated with the YTHDF1 attenuating agent, and optionally a pharmaceutically acceptable carrier. A method for attenuating an activity of YTHDF1, by administering an effective amount of a YTHDF1 attenuating agent. A method for determining whether or not a candidate agent is a YTHDF1 attenuating agent, by contacting the candidate agent with a YTHDF1 mutant. A method for treating a disease, disorder or condition associated with an expression of an antigen in a subject in need thereof.